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1. Introduction
Spatially Fractionated Radiation therapy (SFRT) has a history of
over 100 years. The principle of SFRT is distinctive from the stan-
dard radiation approaches, as it treats the total tumor with a
non-uniform dose, effectively treating the tumor while staying
within normal tissue tolerance of the surrounding structures. His-
torically, SFRT is frequently used to treat bulky malignant tumors
with a high radiation dose in the stereotactic radiosurgery (SRS)/
stereotactic body radiotherapy (SBRT) dose range (10–20 Gy per
fraction) using megavoltage x-ray beams. The application of SFRT,
historically known as GRID therapy, has produced dramatic relief
of severe symptoms, significant objective regression, above aver-
age local control rates and minimal toxicity in palliative settings
[1]. The advancement of physics and technology has provided
more techniques to deliver SFRT. Some understandings of radiobi-
ology and immunology have been generated from studies of SFRT.
These promising clinical results have generated a renewed interest
in this technique at many centers in the United States and interna-
tionally. A series of novel application of SFRT in clinical trials are
being anticipated in the near future. Here, we summarize the his-
tory, the present and the future of SFRT. As current reviews of SFRT
https://doi.org/10.1016/j.ctro.2019.10.004
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are lacking, we present a comprehensive review of SFRT and its
clinical implications.
2. Origination of SFRT with GRID therapy
The original technique to deliver SFRT was called GRID therapy,
which was introduced in 1909 by Kohler and was commonly used
through the 19300s [2]. This type of therapy involved delivering a
relatively high but heterogeneous radiation dose to the tumor
through a perforated screen with blocked areas called a GRID. GRID
was used to create a beam arrangement that is similar to an array
of pencil beams. This delivery of SFRT, does not attempt to treat the
whole tumor like the conventional approaches. Instead, this tech-
nique allows for the delivery of irradiation of SRS/SBRT dose level
in areas within tumors, especially bulky tumors, avoiding produc-
ing prohibitive damage or detrimental toxicities to surrounding
tissues. Thus, skin and subcutaneous tissues can tolerate much
higher doses with SFRT than attempting to cover the whole tumor
with radiation. SFRT was initially delivered via orthovoltage X-rays
to treat advanced bulky or tumors that were deeply seated in the
1950s [3]. With the introduction of megavoltage radiation, skin
sparing and better dosimetry can be obtained easier than ortho-
voltage X-rays. Thus, GRID radiotherapy has become less com-
monly used as a clinical delivery method. In addition, the use of
more modern technology to deliver SFRT with superior dosimetry
to GRID has not been well characterized. Hence, new investigations
are warranted.
3. GRID’s application in megavoltage era
In the 1990s, GRID therapy was delivered with megavoltage
photon beams to treat patients with massive or recurrent tumors
who had underwent previous radiation. Published clinical results
employing GRID therapy have most commonly focused on its use
in the palliative setting. Many reports of patients with large or
recurrent tumors treated with GRID therapy showed patients
achieving good oncological outcomes [1,4–6]. Placement of
10–15 Gy to Dmax was delivered with a single field and a GRID
block with 50:50 (1:1) open to close areas ratio employed. No
acute effects and no unusual late damage were observed in a fol-
low-up time range of 1–18 months [4]. Subsequently, palliative
GRID therapy showed a response rate of more than 90% and com-
plete response (CR) rate of 27% [5]. Another study of 71 patients
with bulky tumors (size > 8 cm) of varying histologies demon-
strated a 78% response in pain improvement, a 59% partial
response (PR) rate, and a 73% objective clinical response rate for
mass effect after GRID therapy of 10–20 Gy with or without addi-
tional external beam radiation [1]. Neither of these studies demon-
strated significant toxicity with GRID therapy. GRID therapy has
also been applied in a definitive setting. Twenty-seven patients
with stage IV localized head and neck cancers received a dose of
15–20 Gy with GRID therapy followed by conventional doses of
external beam radiation [6]. GRID was used either as a definitive
treatment or in the pre-operative setting [6]. Neck control was
reported as 96%, a pathologic complete response rate of 85% was
achieved in those patients that subsequently underwent neck dis-
section. There were no grade 4 toxicities. More recently, 14
patients with bulky head and neck squamous cell carcinomas
received a single fraction of GRID therapy followed by standard
concurrent chemoradiation. These patients experienced a similar
toxicity profile to patients treated with standard chemoradiation
alone, while achieving a gross tumor volume tumor control rate
of 79% [7]. A Summary of publications about GRID therapy is
shown in Table 1. Table 1 summarizes the representative clinical
application studies of GRID therapy from 1990 to 2019. Among
them, all patients treated with GRID therapy were at advanced
stage. Clincal application studies of other SFRT methods are sum-
marized in Table 2, this series of clinical reports demonstrated gen-
erally better than expected relief of severe symptoms, objective
tumor regression, and local control rates with minimal toxicity.
4. Implementation and improvement of GRID therapy
Initially, GRID therapy was generally delivered with a conven-
tional linear accelerator with a GRID block that is either indepen-
Table 1
Clinical application of GRID therapy.
Study Pt# Stage Pathology Sites GRID (Gy) EBRT (Gy) Outcomes Toxicity
Mohiuddin et al.
[4]
22 Advanced Mixed Mixed 10–15 N/A 90% symptoms control N/A
Mohiuddin et al.
[5]












Mixed Lung, & N, GI,
sarcomas, GU, GYN,
Skin, Breast, Liver
10–20 Gy 4000 cGy Cr 0–24%, PR50-85% 1 case developed carotid
blowout
Huhn et al. [6] 27 Bulky N2- N3 Head and
neck
Head and neck 15–20 Gy 54–79 Gy Group1 GRID + RT neck
control rate 93% DSS 50%,
LC 86%.
Group 2 GRID + R T + Sx
neck control rate 92%, DSS
85%, LC 92%









Head and neck 20 Gy 66 Gy 80% pCRin planned neck
dissection or primary
tumor biopsies of the
GRID area
No patient developed
Grade 4 acute toxicity. 1
case of carotid blow-in
after neck dissection. may
have not been attributable
to GRID therapy.
Neuner et al. [59] 79 Bulky tumor
s
Mixed Mixed 10–20 Gy 9–70.2 Gy Pain 74–75%
Mass effect 67–73%








Head and Neck 15 Gy 48–79.2 Gy 81% LC, 9% DM 4% G3+ toxicities
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dently customized or commercially fabricated. Usually only one
radiation field was used for GRID. A commercially available GRID
block is shown in Fig. 1.
Some institutes also use customized GRID block such as a block
with holes created in a square lattice manner so that the passage
will follow photon beam divergence. Alloy was used to fit into
the spaces between the tubes forming the shielded areas of the
GRID [5]. However, physical GRID blocks have some challenges in
clinical practice, such as being heavy to use in the daily practice
and technical challenges in following the divergence of beams.
Due to the wide range of GRID usages and different methodology,
the optimal arrangement of hole diameter and spacing in GRID
blocks has not been defined yet. Monte Carlo simulation was per-
formed to simulate 25 different patterns of Grid blocks. The results
showed that the optimal range of hole diameters should be
between 1.00 and 1.25 cm with spacing of 1.7 or 1.8 cm. GRID
design has major impact on radio-resistant tumors (SF2 > 0.4), thus
appropriate design of the hole diameter and hole spacing may lead
to 40% higher clinical responses (i.e. hole size change from0.5 to
1.1 cm) [8].
With the advancement of modern linear accelerators, MLCs can
be used to create GRID-equivalent dosimetry. MLC-based GRID
therapy has several advantages: 1) LINAC head has pre-installed
MLCs; 2) better dosimetry calculation can be easily achieved
within the treatment planning system; and 3) the flexibility to
change dosimetry accordingly such as hole size and separation.
However, one major issue of MLC-based GRID therapy is the larger
MLC leaf size to form the similar hole size compared to a physical
GRID block and risk for dose spillage to the shielded area under
MLCs generated by GRID blocks [9].
For deep seated bulky tumors, conventional GRID therapy faces
a problem that the high dose falls into the normal tissue, given that
only one single field or two adjacent (non-opposing) fields are typ-
ically used. The adjacent normal tissues usually receive very high
doses when the dose drops off quickly because of larger skin-to-
tumor distance. So, when deep-seated tumors with skin-to-tumor
distances over 8 cm are treated with conventional GRID blocks
with photons, tumor dose coverage posed a challenge. Since then,
modern advanced GRID therapy techniques using Helical
Tomotherapy or Volumetric Arc Therapy techniques have been
developed. (Fig. 2, GRID therapy delivered by Volumetric Arc).
Tomotherapy was used to create a radiation plan that is similar
to the one obtained in an interstitial brachytherapy procedure.
The advantage of Tomo-based GRID is lower normal tissue EUD
(equivalent uniform doses) compared to LINAC-based GRID plans.
In addition, Tomo-based GRID allows better conformity for tumors
that are located in a complex structural relationships with avoid-
ance structures [10].
5. SFRT in the modern 3D era
As described above, 2D GRID therapy often results in the high
radiation dose outside of the radiation clinical target volume.
Hence, Wu et al. [11] developed the concept of 3D LATTICE Radio-
therapy (LRT). Its basic principle is to create multiple localized
high-dose small spheres called vertices with a certain degree of
separation within the tumor volume, while keeping the dose level
lower in the periphery of the tumor to avoid related toxicity. LRT is
the 3D technical extension of 2D GRID technique, the vertices are
strictly contained within the gross tumor volume (Fig. 3). LRT is
based on: 1) the proven clinical effectiveness of GRID therapy
and 2) the new advances in physics and techniques that allow cre-
ating three dimensional (3D) high dose regions concentrated in
small spheres called vertices inside the tumor volume possible
[1,11]. LRT has been utilized clinically in patients with bulky dis-
ease and has resulted in improved local control without added tox-
icity [12]. Amendola et al used LRT in the largest extent so far, they
have treated cancers located in pelvic and chest [13]. They have
safely delivered LRT to 10 patients with advanced stage NSCLC
resulting in a statistically significant reduction in tumor size and
in long overall survival in patients deemed hospice candidates. This
was associated with no significant morbidity or mortality. LRT dose
was 18 Gy in the vertices; the size of vertices range from 1 to 2 cm,
the ratio of the dose between the vertices and the entire tumor vol-
ume is less than 3%. The average distance between vertices (center
to center) was 3.6 cm [14].
Table 2
Clinical Application of other SFRT methods.
Study Pt
#
Stage Pathology Technique GRID (Gy) EBRT (Gy) Clinical outcome s Toxicity
Zhang et al.
[10]
10 N/A Mixed Helical Tomotherapy
And LINAC based GRID
Dmax 20 Gy








LRTX1 (18 Gy to
vertices and 3 Gy to
GTV),
EBRT 45- 66 Gy Tumor Volume response
15–83% mean 52%.
OS 4–86 months, mean
22 months
Grade1 pneumonitis















Fig. 1. Clinical GRID block commercially available from decimal, LLC, photo
provided by decimal, LLC.
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There is no systematic guidelines of vertices placement in LRT
therapy so far.
6. SBRT with SFRT–SBRT-PATHY
Stereotactic body radiation therapy [SBRT] uses specialized
devices to immobilize and position patient to ensure precise deliv-
ery of high dose radiation to tumor using coordinates. For example,
the results with SBRT/stereotactic ablative radiotherapy [SABR] in
early-stage lung cancer patients have shown local control rates
up to 86% [15], exceeding the control rates previously demon-
strated with conventionally fractionated radiation. Recent atten-
tion to oxygen sensing research has suggested that intratumor
hypoxia leads to increased Hypoxia-inducible factors (HIFs) activ-
ities, which leads to the activation of down-stream pathways for
angiogenesis [16], cancer stem cell survival [17], immune evasion
[18] and potential resistance to radiation therapy [19]. Thus, when
hypoxic core of tumor is specifically targeted by SBRT, there might
be novel radiation induced changes in the tumor environment that
is yet to be studied and contributed to the improved outcomes.
Radiomics method has been used to assess tumor-infiltrating
CD8 cells and to predict the clinical outcomes of patients’ response
to anti-PD-1 immunotherapy [20]. Tumor microenvironment has
Fig. 3. Lattice vs GRID in same lung case (Photo Credit Dr. XiaodongWu) – (Lattice is a 3D way of delivering GRID and can decrease the dose in peripheral tissues compared to
2D GRID).
Fig. 2. GRID therapy delivered with Volumetric Arc, (photo credit Dr. Waleed Mourad University of Kentucky) DVH and GRID dosimetry on Axial, Coronal and Sagittal Planes
demonstrated in treatment planning system.
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been suggested to be inhomogeneous, which suggested that given
intra-tumor areas are more resistant/aggressive than others [21].
For example, severe hypoxic areas in tumor will need higher (abla-
tive) doses compared to nonhypoxic areas, which could be cured
with current dose level from conventional radiation therapy, as
suggested by dose response models [22]. Thus, several intra-tumor
boosting strategies have been proposed, which includes a micro-
boost to the high risk/tumor harboring area in the prostate gland
while sparing the entire gland from uniform dose-escalation to
avoid excessive toxicity to bladder and rectum [23,24]. These
strategies matched with the concept of SFRT and can be applied
to other tumor sites. A recent study using SFRT concept delivered
stereotactic body radiation therapy of PArtial Tumor irradiation
(SBRT-PATHY) targeting exclusively the HYpoxic segment of unre-
sectable bulky tumors. The treatment triggered bystander effects
(local) and abscopal effects (distant). SBRT-PATHY alone showed
an overall response rate (96%) devoid of toxicity (grade 1–4: 0%)
and 52% of patients presented abscopal effects [25]. Fig. 4 shows
the radiobiology of the bystander effect-induction by SBRT-PATHY.
7. SFRT with particle therapy
GRID is being utilized with protons as well, since protons have
the unique advantage of minimizing or even eliminating exit dose
in normal tissues located beyond the tumor due to its inherent
property (i.e. the Bragg peak) and potentially less scattering in nor-
mal tissues [26]. When proton is used instead of photon in GRID
therapy, it successfully replicated the valley-to-peak ratios inside
tumor. The depth-dose curve dropped quickly beyond the target
and resulted in a more uniform beamlet dose within the tumor.
Proton PBS has been tested in patients and can reduce the dose
to proximal organs when treating a deep-seated tumor [26].
Carbon-ion beam has been evaluated for GRID treatment, GRIDs
containing 0.5 or 3 mm wide carbon ion beam share similar char-
acteristics with GRID therapy. If carbon ion beam grids are cross
fired in a GRID manner, then it is feasible to produce homogenous
dose distribution in the tumor while sparing normal tissue as well
[27].
8. The evolution of SFRT in the smaller dimensions
Microbeam is a narrow beam of radiation with a beam size of
micrometer or sub-micrometer dimensions. In 1960 s Woodley
et al reported that mimicking heavy particles in space that is
around 25 lm in diameter, a microbeam that is in that size range
can increase the tolerance of mice brain to radiation significantly
(4000 Gy vs 150 Gy) [28]. Consequently, Slatkin et al. studied the
synchrotron-generated X-ray microbeams, they found that brain
tissues are spared if high dose of radiation is given in a spatially
spaced manner with micorobeams [29]. Hence, the European Syn-
chrotron Radiation Facility (ESRF) in Grenoble, France, assembled a
micro beamline for preclinical experiments and clinical trials [30].
Microbeam Radiation Therapy (MRT) uses X-ray microbeams (typ-
ically around 50–600 keV) in a collimated array manner. MRT has
intrinsic characteristics like high dose rate and minimal beam
divergence. High dose rates are necessary to deliver high therapeu-
tic doses in microscopic volumes. The minimal beam divergence
achieves a higher dose deposition in the target volume. Typically,
MRT uses arrays of narrow microplanar. MRT can deliver peak
entrance doses in the range of several hundred Grays which prefer-
ably kills tumors and does not lead to added toxicities in normal
tissues. MRT does selectively ablates neurons in CNS but can out-
standingly preserve normal brain tissues from necrosis. For exam-
ple, when rats are exposed to MRT with peak/-valley doses of 357/
12.7 Gy, only 2/10 developed late paresis. However, when single
beam was used to deliver radiation, the ED50 for paralysis in rats
was 130 Gy. Therapeutic ratios of MRT in small animal models
have exceeded those from pre-clinical radiotherapy trying to cover
tumor with conformal dose across a range of malignancies [31].
MRT improved survival in rat model. However, MRT has not been
reported in large animals to date. The translation of MRT to clinical
application faces 2 major challenges, accurate positioning of the
beam and the patient; major transition of thinking and notions
in radiation oncology field to accept inhomogeneous dose in treat-
ment and prescribing/standardizing new MRT/SFRT treatment
[30].
Fig. 4. The radiobiology of the bystander effect-induction by SBRT-PATHY. (Photo Credit Dr. Slavisa Tubin). The figure summarizes the radiobiology of the bystander effect-
induction by SBRT- PATHY. An 18F-FDG PET combined with a contrast-enhanced CT was used for the definition of BTV (smaller yellow contour), which corresponds to the
junctional region between the central necrotic segment (black region) and the contrast- enhanced, hypermetabolic peripheral tumor (red contour, not targeted for
irradiation). The red arrows represent ‘‘anti-angiogenic bystander signal” (blue pellets) released by the irradiated hypoxic tumor, inducing the regression of the non- targeted
tumor. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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9. Radiobiology findings from GRID therapy
Current understanding about radiobiology behind GRID therapy
may involve the bystander effect, vascular damage, and anti-tumor
immune responses. The term bystander effect describes the ability
of cells affected by irradiation to convey manifestations of damage
to other cells not directly targeted for irradiation [32]
Bystander effect in GRID therapy is mostly referring to the
changes happened in cells that are located in the valley (low dose)
regions. Griffin et al. [33] demonstrated significant bystander kill-
ing in cells that are located next to high-dose radiated regions with
GRID therapy. Plus, the killing of cells in the regions that was not
directly radiated was found to be higher than those generated by
background or scatter doses, which suggested that high dose GRID
irradiation (10 Gy) triggered true cytotoxic bystander effects and it
is possible that low doses of irradiation may also increase CD8 T
cell recruitment to these areas whereas higher doses may lead to
lethal effects within these newly recruited cells during radiother-
apy. These bystander effects are not observed with conventionally
fractionated radiation which encompass the entire region of the
tumor. TNF-a [34] and TRA IL [35] have been suggested to play a
role in bystander effects. These factors were induced by cells that
received high dose under open areas of GRID [36,37]. These factors
could theoretically trigger bystander effects in the cells that were
next to high-dose regions. These data suggest that GRID therapy
can induce a different mechanism of tumor cell killing to that from
conventional radiotherapy approaches, this mechanism is espe-
cially appealing in tumors that are bulky or has hypoxic cores.
Work from Garcia-Barros et al. [38] has suggested that ‘‘high dose”
radiation of 15 Gy causes an environment of ‘‘Potential Lethal
Damage” that makes these cells sensitive to further doses of radi-
ation, especially the endothelial cells of the tumor microvascula-
ture. Ceramide is generated from sphingomyelin by SMase, it has
been shown to be involved in sensitizing microvascular endothelial
cells to radiation induced apoptosis.[38] When the activity of
Secretory SMase and the concentration of ceramide were measured
in patients who received SFRT using GRID therapy, an increase in
SMase activity and ceramide levels was found only in patients with
complete or partial response to the SFGRT, but not in non-respon-
ders.[39] Based on current knowledge, each endothelial cell in
tumor vasculature supplies to a segment/unit of thousands of
tumor cells. Thus, killing endothelial cell or occlusion of small cap-
illaries inside of tumor would lead to an avalanche of death of
tumor cells [40]. Data from mice model has suggested
that > 10 Gy/fraction of radiation can lead to severe vascular dam-
age and decreased blood supply. Also, delayed secondary tumor
cell death has been shown to occur after 15–30 Gy of radiation in
animals due to changes in intratumor microenvironment after
radiation induced blood vessel obstruction. This would be a plausi-
ble explanation for the debulking effect from GRID therapy [41].
10. SFRT and immune responses
Radiation induced regression of cancer that was not directly
radiated was called the abscopal effect. The abscopal effect has
been attributed to activation of immune system. Today, the con-
sensus is that combining radiotherapy with immunotherapy might
increase abscopal response rates [42]. Current understanding of
optimal radiation dose to elicit an immune response appears to
be in the range of 8 and 10 Gy per fraction commonly delivered
in 1– 3 fractions [42], suggesting that sufficient number of tumor
lysates or extent of tumor necrosis and neoantigen release are
needed to induce specific immune responses. Peters et al. reported
that GRID/SFRT can trigger robust abscopal effect in tumors that
are not directly irradiated: their mice model was treated with high
dose SFGRT and showed increased cell death in the unirradiated
tumor when compared to the mice that received open field radia-
tion [43]. In addition, some preclinical data have shown SFRT can
elicit both local and metastatic/distant tumor control through trig-
gering immune responses. Single fraction SFRT significantly
delayed un-irradiated distant tumor growth in a mice Xenograft
tumor model. SFRT induced increased secretion of inflammatory
cytokines and infiltration of T-cells increased significantly in the
right sided un-irradiated tumor after irradiation with SFRT to
50% tumor volume in the left sided leg tumor [44]. This suggested
that the cellular immunity might play a role in SFRT-triggered
abscopal response. Clinical data have shown that partially irradi-
ated tumor can become immunogenic. Abscopal effects have been
triggered in patients by using a high, single dose of radiation to tar-
get the hypoxic segment of tumor with image-guided treatment
planning and delivery [25]. A recent phase 2 randomized control
trial in NSCLC patients demonstrated that SBRT can convert a cold
tumor into a hot tumor. Patients that were PD-L1 low saw signifi-
cant improvement when pembrolizumab and SBRT were combined
compared with pembrolizumab alone [45].
11. Tumor types that could benefit from SFRT
Outcomes from tumors with different histological characteris-
tics and treatment sites from historical clinical outcomes from
GRID therapy have been summarized by Meigooni et al. [8]. The
clinical total response rates with grid therapy were as following:
Osteosarcoma (100%), Liposarcoma (50%), Leiomyosarcoma
(100%), Colorectal (100%) (4); Sarcoma (94%), SCC (92%), Melanoma
(83%), Adenocarcinoma (69%) [4]; Sarcoma (83%), SCC (94%), mela-
noma (50%) [5]; SCC of H&N (93%) [6]; Parotid (0%), Base of tongue
(30%) Maxillary sinus (50%), Nasopharynx, Retromolar trigone, and
Larynx (100%) Tonsil (25%) [7]. A few publications have highlighted
that SFRT may be useful in radiation-resistant tumors, such as sar-
coma. A case study used a total of 32 Gy by cEBRT following 18 Gy
by SFGRT in a very large spindle cell sarcoma. The pre-treatment
tumor volume is 631 cm3 and the postoperative pathology demon-
strated 65 cm3 of residual tumor. Surgical specimen showed only
5–10% viable cells with extensive fibrosis and necrosis. Thus, a
treatment response of 90% was seen in this case report, which
was dramatic in comparison to studies with a 0– 0.5% radiological
regression rate for 50 Gy EBRT alone [46]. A mechanism study of
effectiveness of GRID therapy was done with The Monte Carlo sim-
ulation techniques to simulate the dose distribution profiles from
GRID blocks. The therapeutic ratio (TR) and the equivalent uniform
dose (EUD) for different types of tumors with respect to their radi-
ation sensitivities were calculated using the simulated dose pro-
files and linear quadratic (LQ) and the Hug–Kellerer (H-K)models.
Their results showed that TR of radioresistant tumor is known to
increase with prescribed dose in grid therapy, but the TR of radio
sensitive tumor does not change significantly with dose. Hence,
grid therapy is expected to be biologically be more effective for
radioresistant tumors [8].
12. Likely future Evolution of SFRT
12.1. Delivery techniques
Minibeam (MBRT) has beam widths around 500–7 00 lm
(interbeam distance being the double of the width) which is wider
than MRT (beamwidth 25 to 100 lm). The irradiation is performed
by using an array of parallel thin beams spaced by 1 to 3 mm. Like
MRT, MBRT is also typically delivered by synchrotron beams con-
sisting of very intense kilovoltage x-rays. So far studies have indi-
cated that beam dimensions beyond 0. 68 mm is a threshold for
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MBRT ‘s tissue-sparing effect [47]. MBRT has advantage in its
thicker beam and dose profiles that they are not effected by cardiac
pulsations like MRT [48]. It does not require very high dose rate
like MRT and the implementation is technically easier than in
MRT [49]. To bypass the high cost and geographical limitations of
synchrotron, a small animal radiator has been developed to deliver
minibeam patterns with peak-to-valley dose ratio (PVDR) values
similar to those at synchrotrons and dose rate feasible for one frac-
tion in a time compatible with rodent’s anesthesia. MBRT was
delivered successfully (20 Gy in one fraction) to rodents with less
severe skin damage and almost no brain damage compared to tra-
ditional radiation group [49]. Carbon ion minibeams with 525um
beam thickness were used at the NASA Space Radiation Lab oratory
(NSRL) in an ‘‘interlaced” (or ‘‘interleaved”) geometry to ab late a
6.5 mm target in the rabbit brain without major damage to the
brain. While Proton MBRT was performed with 400-lm beam
-wide slits and 3200-lm center-to- center spacing in glioma bear-
ing rats. A 70 Gy peak dose in one fraction was delivered to whole
brain, pMBRT leads to a significant tumor control and tumor erad-
ication in 22% of the cases and no substantial brain damage [50].
The advantage of carbon minibeams over conventional carbon
therapy is that the radiation impact on the non-targeted tissues,
particularly the proximal tissues is lower. Which can allow dose
escalation in treating radioresistant tumors. Similarly, proton
minibeams save the skin and the proximal tissues better than con-
ventional proton therapy. Both proton and carbon ion minibeams
can be delivered with a collimator in beam path with current
charged particles therapy facilities [51].
12.2. Precision medicine/radiotherapy
A point for SFRT and conventional radiation therapy to merge is
precision radiotherapy, which is covering whole tumor with inho-
mogeneous dose. However, the inhomogeneous dose is designed/
selected by the biological differences within the tumor, such as
radiosensitivity, tumor aggressiveness or the nature of mutations
in genes or pathways in a given intratumor loci. With development
of radiomics, tumor homogeneity is being explored. Intratumoral
subregions have been identified and could be used for prediction
of tumor prognosis [52]. For example, one of the subregions in lung
tumors (NSCLC) that is associated with the most metabolically
active, heterogeneous component of the tumor was defined as
the ‘high-risk’ subregion, the volume of which can predict distant
metastasis and overall survival in patients treated with radiation
therapy [52]. Precision radiotherapy in a different name, adaptive
dose painting by number (DPbN), has been attempted in clinical
treatment planning studies: FDG-PET/CT images was used to
acquire tumor voxels, tumor voxel was then used to create a
domain and used to calculate the probability of achieving local
control with standard radiation 35X2Gy dose. The study showed
that most human PPV negative tumors require a treatment
dose > 100 Gy to certain local tumor regions and this is not likely
achieved by 35 X 2 Gy but could be achieved by adaptive dose
painting by number (DPbN) [53]. Thus, high-risk tumor sub
regions, which harbors aggressive cancer cells, can be targeted
with SFRT concepts/methods to improve local control and patient
survival. The concept of SFRT can be incorporated into daily radia-
tion planning as well. Fig. 5 summarized this article in a lively
manner, SFRT was placed on top and traditional radiation therapy
is on the bottom. It is interesting to see that SFRT and traditional
radiation therapy grows together like yin and yang. And every
major ways of delivery of tradition radiation can be creatively used
to deliver SFRT. (Fig. 5. Evolution of SFRT along traditional radia-
tion therapy)
13. Advantages of SFRT
An easy analogy of SFRT is precision-guided munition in mili-
tary, which is intended to be precisely delivered to a given target,
inflict lethal damage to the target and minimize collateral damage
other than the target [54]. The advantage of SFRT in medicine lies
in increased firepower (high BED), increased precision and less tox-
icity. Increased firepower (high biological equivalent dose (BED)) is
a key factor in the success of SBRT treating early stage lung cancers
Fig. 5. Evolution of SFRT with traditional radiation therapy.
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as Onishi et al. [55] demonstrated in a review that a better local
control and survival rates are generated when a BED of 100 Gy or
more is achieved. For SBRT or SABR, increased toxicity has been
reported when targets are larger (>5–7 cm) or adjacent to critical
normal structures, which limits the application of current practice
of SBRT/SABR [56,57]. As indicated in ASTRO guideline, application
of SBRT in centrally located tumors is associated with unique and
significant risks [58]. Hence, SBRT in lung cancer is, therefore, more
commonly delivered for patients with small peripheral tumors;
SFRT can easily achieve BED of > 100 Gy in a given tumor volume
even in bulky or centralized tumor without the current limit of
SBRT/SABR.
14. Conclusion
SFRT is important in its concept of covering whole or partial
tumor with inhomogeneous radiation dose and gives the field
more creativity and complimentary applications to supplement
standard school of radiation therapy. While its clinical use to date
has been limited to select centers, most commonly for palliative or
recurrent cases, SFRT does have potential in treating primary can-
cers in a definitive manner such as head and neck, lung, breast,
gynecologic and sarcoma cases. Clinical trials incorporating SFRT
as a boost or as the primary radiotherapy component are war-
ranted. The future application of the concept of SFRT will depend
on technology advancement and more understandings of the bio-
logical mechanism in tumor or normal tissues radiated with SFRT.
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